Ready-to-Dilute Pemfexy Gains Additional NSCLC Indication
Pemfexy (pemetrexed) plus pembrolizumab and platinum chemotherapy is now approved for the initial treatment of patients with metastatic, nonsquamous NSCLC.
Pemfexy (pemetrexed) plus pembrolizumab and platinum chemotherapy is now approved for the initial treatment of patients with metastatic, nonsquamous NSCLC.
The FDA has approved the gene therapy Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.
Project Renewal is an Oncology Center of Excellence initiative that aims to update the labeling information for certain older oncology drugs.
In mouse models, WP1122 outperformed temozolomide.
The approval was based on data from the phase 2 KRYSTAL-1 study.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
Omburtamab is an investigational radiolabeled monoclonal antibody designed to target tumor cells that express B7-H3.
The decision to withdraw the indication was made based on findings from the phase 3 IMvigor130 trial.
Bebtelovimab is not expected to neutralize the SARS-CoV-2 variants BQ.1 and BQ.1.1, which are the most prevalent variants in the United States.
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.